| 摘要 |
The present invention relates to a final drug product comprising IGF-I or any functional analogue thereof in an aqueous solution with a reduced concentration of oxygen. In this way, the IGF-I purity can be retained during storage to a surprisingly high degree. The IGF-I purity can be retained for a prolonged period of time, if the final drug product further comprises an inert gas and/or an antioxidant. The present invention also relates to processes for reducing the oxygen concentration of the aqueous solution, and a method for improving the stability of IGF-I in an aqueous solution by storing the solution under an inert gas atmosphere. |
